Bristol-Myers Squibb Co (BMY)
45.26
+0.56
(+1.25%)
USD |
NYSE |
Apr 26, 14:43
Bristol-Myers Squibb Cash from Investing (Quarterly): -1.346B for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.346B |
| September 30, 2023 | -410.00M |
| June 30, 2023 | -329.00M |
| March 31, 2023 | -210.00M |
| December 31, 2022 | 1.213B |
| September 30, 2022 | -2.081B |
| June 30, 2022 | -289.00M |
| March 31, 2022 | 95.00M |
| December 31, 2021 | 401.00M |
| September 30, 2021 | -976.00M |
| June 30, 2021 | 180.00M |
| March 31, 2021 | -143.00M |
| December 31, 2020 | -11.81B |
| September 30, 2020 | -213.00M |
| June 30, 2020 | 556.00M |
| March 31, 2020 | 610.00M |
| December 31, 2019 | -12.18B |
| September 30, 2019 | 491.00M |
| June 30, 2019 | 715.00M |
| March 31, 2019 | 1.06B |
| December 31, 2018 | -1.462B |
| September 30, 2018 | -147.00M |
| June 30, 2018 | -348.00M |
| March 31, 2018 | -43.00M |
| December 31, 2017 | 1.019B |
| Date | Value |
|---|---|
| September 30, 2017 | 142.00M |
| June 30, 2017 | -1.024B |
| March 31, 2017 | -203.00M |
| December 31, 2016 | 16.00M |
| September 30, 2016 | -368.00M |
| June 30, 2016 | 406.00M |
| March 31, 2016 | 1.426B |
| December 31, 2015 | -984.00M |
| September 30, 2015 | -62.00M |
| June 30, 2015 | -1.28B |
| March 31, 2015 | 754.00M |
| December 31, 2014 | 351.00M |
| September 30, 2014 | 164.00M |
| June 30, 2014 | -1.511B |
| March 31, 2014 | 2.212B |
| December 31, 2013 | -315.00M |
| September 30, 2013 | -475.00M |
| June 30, 2013 | 57.00M |
| March 31, 2013 | 161.00M |
| December 31, 2012 | 277.00M |
| September 30, 2012 | -4.203B |
| June 30, 2012 | 226.00M |
| March 31, 2012 | -3.027B |
| December 31, 2011 | 495.00M |
| September 30, 2011 | -163.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-12.18B
Minimum
Dec 2019
1.213B
Maximum
Dec 2022
-1.354B
Average
-210.00M
Median
Mar 2023
Cash from Investing (Quarterly) Benchmarks
| Amgen Inc | -27.09B |
| Gilead Sciences Inc | -727.00M |
| Johnson & Johnson | -1.202B |
| Karuna Therapeutics Inc (DELISTED) | 92.44M |
| 2seventy bio Inc | 47.89M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.252B |
| Cash from Financing (Quarterly) | 967.00M |
| Free Cash Flow | 12.65B |
| Free Cash Flow Per Share (Quarterly) | 1.929 |
| Free Cash Flow to Equity (Quarterly) | 1.754B |
| Free Cash Flow to Firm (Quarterly) | 4.255B |
| Free Cash Flow Yield | 13.45% |